← 홈

전체 프로그램

ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 227개
CGTBiologicstaleThe Methodist Hospital Research…Phase 2

IL-12 gene therapy (IL-12 gene therapy)

Triple Negative Breast Cancer; Anthracycline-refractory TNBC · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4
효능 ORR 90%임상시험 1상태 DISCONTINUED
CGTBiologicstaleThe First Hospital of Jilin Uni…Phase 2

IL-15-armored CAR-T cells (IL-15-armored CAR-T cells)

Relapsed/Refractory Multiple Myeloma; Plasma Cell Leukemia (PCL) · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5
효능 ORR 50%임상시험 1상태 RECRUITING
AntibodystaleChinese Academy of Medical Scie…Phase 2

Ibrutinib Combined With Rituximab (Ibrutinib Combined With Rituximab)

DLBCL; MYD88 Gene Mutation · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
CGTBiologicstaleTcelltech Inc.Phase 1

In Vivo CAR-T Therapy (In Vivo CAR-T Therapy)

Relapsed or Refractory Hematologic Malignancies · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleDonghua ZhangPreclinical

Infusion of BAFFR CAR-T therapy for relapsed/refractory B-cell malignancies (Infusion of BAFFR CAR-T therapy for relapsed/refractory B-cell malignancies)

Relapsed/Refractory B-cell Malignancies · FRα

#FR#CGT#Preclinical#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
AntibodystaleSanofiPhase 2

Isatuximab SC-OBDS (Isatuximab SC-OBDS)

Plasma Cell Myeloma Refractory · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
CGTBiologicstaleCancer Institute and Hospital, …Phase 1

KSX01-TCRT cell therapy (KSX01-TCRT cell therapy)

Refractory Solid Tumors; Relapsed Solid Tumors · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleNanjing Legend Biotech Co.Phase 1

LCAR-B4822M CAR-T Cell Immunotherapy (LCAR-B4822M CAR-T Cell Immunotherapy)

Refractory or Relapsed Multiple Myeloma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleNanjing Legend Biotech Co.Phase 1

LUCAR-20SP cells (LUCAR-20SP cells)

Relapsed B-cell Non-Hodgkin Lymphoma; Refractory B-cell Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleNanjing Legend Biotech Co.Phase 1

LUCAR-G79 T cells (LUCAR-G79 T cells)

Relapsed/Refractory Autoimmune Diseases · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleMiltenyi Biomedicine GmbHPhase 2

MB-CART20.1 (MB-CART20.1)

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleMemorial Sloan Kettering Cancer…Phase 1

MCARH109 (MCARH109)

Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleMemorial Sloan Kettering Cancer…Phase 1

MCARH125 (MCARH125)

Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
AntibodystaleMonopteros Therapeutics Inc.Phase 1

pembrolizumab (Keytruda, MPT-0118 + pembrolizumab)

Solid Tumor, Adult; Advanced Solid Tumor · FRα

#FR#Antibody#Phase1#항체#면역항체+5
임상시험 1상태 ACTIVE
ADCBiologicstaleShanghai Miracogen Inc.Phase 1

MRG001 (MRG001)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab (Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab)

Refractory Metastatic Colorectal Cancer · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
CGTBiologicstaleImcyse SAPhase 2

Multi-epitope (ME, Multi-epitope, Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) vaccine)

Prostatic Neoplasms; Neoplasms of Prostate · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4
효능 ORR 2.4%임상시험 1상태 ACTIVE
CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

Multi-epitope (ME, Multi-epitope, Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine)

Prostatic Neoplasms; Prostate Cancer · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4
효능 ORR 2.4%임상시험 1상태 DISCONTINUED
CGTBiologicstaleNkarta, Inc.Phase 1

NKX101 - CAR NK cell therapy (NKX101 - CAR NK cell therapy)

Relapsed/Refractory AML; AML, Adult · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING

9 / 12 페이지

← 이전다음 →